Home » Newsletters » BioWorld Science

BioWorld Science

May 21, 2014

View Archived Issues

Takeda Pharmaceutical discloses new CH24H inhibitors

Astex Therapeutics patents novel IAP inhibitors for cancer

Novel biomarkers for Cushing's syndrome, HDR syndrome and MEN1 identified

Preclinical and early clinical data presented for prodrug of Debio-1452

Enantiomer switching of an existing drug unveils novel mechanism of action against cancer cells

GSK-2339345 proves safe in phase I trials for chronic cough

Kymab secures funding to advance clinical development of antibody therapeutics

FDA orphan status granted to diazoxide choline

ADC Therapeutics and MedImmune to advance ADCT-401 into clinic

Phase II results presented for relamorelin in chronic constipation, diabetic gastroparesis

Cellceutix reports promising findings for brilacidin in diabetic wound model

Sorrento Therapeutics discloses new antibodies for S. aureus infection

KineMed and CHDI Foundation expand Huntington's disease collaboration

Provista Diagnostics initiates clinical study of blood assay for breast cancer

Senesco Technologies completes acquisition of Fabrus

Agenix to sell its tenofovir prodrug

BioAlliance's Livatag receives FDA fast track designation

Ophthotech licenses ex-U.S. rights to Fovista to Novartis

Bioenergenix discloses novel hPASK inhibitors

Dainippon Sumitomo Pharma synthesizes new mGlu5 receptor modulators

MOR-208 receives FDA and EMA orphan drug designations

AADi in-licenses nanotechnology-based drug

Merck KGaA proposes global alliance against schistosomiasis

GSK and Genmab report topline data from pivotal head-to-head study of ofatumumab

Isis Pharmaceuticals begins phase I study of ISIS-PKK-Rx

Takeda achieves FDA approval for vedolizumab

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...